Belite Bio (BLTE) Net Cash Flow (2024 - 2025)
Belite Bio's (BLTE) quarterly Net Cash Flow came in at $196.0 million in Q4 2025, up 2039.73% year-on-year from $9.2 million in Q4 2024, and up 2039.73% quarter-over-quarter from $9.2 million in Q4 2024.
Belite Bio (BLTE) Net Cash Flow (2024 - 2025) Analysis & Trends
Belite Bio's Net Cash Flow history runs 2 years deep, the most recent figure standing at $196.0 million for Q4 2025.
- On a quarterly basis, Net Cash Flow rose 2039.73% year-over-year to $196.0 million in Q4 2025; TTM through Mar 2026 was $196.0 million, a 2039.73% increase from a year earlier, with the FY2025 full-year figure at $321.1 million, up 671.31% from the prior year.
- Net Cash Flow improved to $196.0 million in Q4 2025 per BLTE's latest filing, from $9.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $196.0 million in Q4 2025 and bottomed at $9.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 57.19 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 60.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 196.00 Mn |
| Dec 31, 2025 | 196.00 Mn |
| Dec 31, 2024 | 9.16 Mn |
| Dec 31, 2024 | 9.16 Mn |